In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Celyad (CYAD). The company’s shares closed last Monday at $10.55, close to its 52-week low of $8.10.
According to TipRanks.com, Roy is a 4-star analyst with an average return of 11.2% and a 44.3% success rate. Roy covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Aeglea Biotherapeutics, and Mirati Therapeutics.
Currently, the analyst consensus on Celyad is a Strong Buy with an average price target of $43.00, representing a 295.6% upside. In a report issued on December 10, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.36 and a one-year low of $8.10. Currently, Celyad has an average volume of 49.69K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.
